B6;129-Cd79b^tm3Mnz/J

Stock number: 008822
Research areas: Immunology, Inflammation and Autoimmunity Research

Description

The cytoplasmic domain of the targeted Cd79b antigen(Igβ) gene was replaced with the cytoplasmic domain of the Cd79a antigen (Igα) gene. Mutant B cells are able to complete all stages of development, but fail to differentiate into B1a cells. Igβc-α cells are anergic to T-independent and T-dependent antigens in vivo. This strain may be useful in studies of B cell development.

Detailed description

The cytoplasmic domain of the targeted Igβ gene was replaced with the cytoplasmic domain of the Igα gene. Mutant B cells are able to complete all stages of development, but fail to differentiate into B1a cells. Igβc-α cells are anergic to T-independent and T-dependent antigens in vivo. This strain may be useful in studies of B cell development.

Development

Positions 183-228 of the Igβ/Cd79b gene were replaced with a cytoplasmic tail segment (positions 161-220) of the Igα/Cd79a gene followed by a TGA stop codon. A loxP-flanked neomycin resistance cassette placed 5' of the targeted mutation was later excised with Cre. A 129/Sv-derived embryonic stem cell line was used to create the mutation. This line was backcrossed three times to C57BL/6 by the donating laboratory.

Allele

Symbol: Cd79b^tm3Mnz
Name: targeted mutation 3, Michel C Nussenzweig
MGI accession ID: MGI:3768659
Generation method: Targeted
Marker symbol: Cd79b
Marker name: CD79B antigen
Chromosome: 11
Strain of origin: 129/Sv
Molecular note: The cytoplasmic tail from amino acid position 183 to 228 was replaced with the cytoplasmic tail of Cd79a from amino acid position 161 to 220. A stop codon follows the last amino acid of the inserted Cd79a segment. A floxed neo cassette was inserted downstream of the Ig domain and subsequently removed by cre-mediated recombination. The presence of the modified protein and the absence of the full length endogenous transcript was confirmed by western blot analysis on B cell lysates.